- News & Analysis
Page 1004
Symphogen for Europe's largest drugs round
Novo, a $20bn quasi-corporate venturing investment company wholly owned by the Novo Nordisk Foundation, is leading a $130m round for Symphogen.
Jan 7, 2011Shire steps into DBV's C round
InnoBio Fund and Lundbeckfond Ventures lead $25.5m round for DBV Technologies, which includes Shire.
Jan 6, 2011GSK and Genzyme invest in Longwood fund
Longwood Founders Management raises $85m for its first fund with GlaxoSmithKline and Genzyme among its limited partners.
Jan 5, 2011JJDC and MP join Genocea
Johnson & Johnson Development Corporation and MP Healthcare Venture Management join drugs peer GlaxoSmithkline in backing Genocea Biosciences.
Jan 5, 2011PneumRx raises $33m for European expansion
Forbion Capital Partners, which span out from Dutch bank ABN Amro at the end of 2006, and Endeavour Vision join as new investors in PneumRx.
Jan 5, 2011Shire agrees first venturing deal
Drugs group Shire gains management commitment to corporate venturing.
Jan 4, 2011Bonovo Orthopedics raises $10m
Legend Capital and OrbiMed Asia Partners join consortium investing $10m in Bonovo Orthopedics.
Dec 30, 2010Merck Serono joins EpiTherapeutics
Merck Serono Ventures joins extended seed round for EpiTherapeutics, which has raised DKr51.5m ($9.2m) since launching in October 2008.
Dec 30, 2010Accera raises $11m
Inventages and Posco previous backers of drugs company Accera, which has raised an $11m round.
Dec 23, 2010About us
GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits our membership, providing privileged access to all our services and resources.
Navigation
© 2026 Mawsonia Ltd. All rights reserved.test regLogin